Several guidelines propose the use of Ki67 expression to select which patients with early stage breast cancer and 1–3 positive nodes should not receive adjuvant chemotherapy. In this Perspective, the authors discuss why, in 2015, the oncologist should not rely on the use of this biomarker for decision-making in this patient population—owing to lack of analytical validity of Ki67 staining, its poor performance for prognostic purposes, and no strong evidence indicating that Ki67 staining predicts the efficacy of adjuvant chemotherapy.
- Fabrice Andre
- Monica Arnedos
- Suzette Delaloge